Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;27(1):395-397.
doi: 10.1007/s12094-024-03560-y. Epub 2024 Jun 14.

Letter to editor response: "Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Controversies and Discussion"

Aylen Vanessa Ospina  1 , Sergio Bolufer Nadal  2 , Bartomeu Massuti Sureda  3 , Mariano Provencio  4
Affiliations

Letter to editor response: "Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Controversies and Discussion"

Aylen Vanessa Ospina et al. Clin Transl Oncol. 2025 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: AVO reports consulting fees from Astra Zeneca, Pfizer, BMS, Merck Serono, Takeda, Roche. Payment or honoraria from Pfizer, Janssen, BMS, MSD, Astra Zeneca. Support for attending meetings and/or travel from Roche, Pfizer, MSD, Roche and Takeda. SBN has no conflict of interest. BMS reports payment or honoraria from Roche, BMS, MSD, Boehringer Ingelheim and Pfizer. MP reports consulting fees from BMS, Astra Zeneca, MSD, Roche, Takeda. Support for attending meetings and/or travel and Payment or Honoraria from BMS, Astra Zeneca, MSD, Roche and Takeda. Ethical approval and Informed consent: Not applicable.

References

    1. Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413–22. - DOI - PubMed
    1. Provencio M, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal Rubio J, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40(25):2924–33. - DOI - PubMed - PMC
    1. Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, et al. Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2023;389(6):504–13. - DOI - PubMed
    1. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85. - DOI - PubMed - PMC
    1. Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389(18):1672–84. https://doi.org/10.1056/NEJMoa2304875 . (Epub 2023 Oct 23 PMID: 37870974). - DOI - PubMed

LinkOut - more resources